2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2022
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis
Deodhar A, Chakravarty SD, Shiff NJ, Lo KH, Xu S, Hsia EC, Danve A, Reveille JD. Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis. JCR Journal Of Clinical Rheumatology 2022, 28: 420-423. PMID: 35649533, PMCID: PMC9704810, DOI: 10.1097/rhu.0000000000001857.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAnkylosisAntibodies, MonoclonalAntirheumatic AgentsHumansSpondylitis, AnkylosingTreatment OutcomeTreatment of axial spondyloarthritis: an update
Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nature Reviews Rheumatology 2022, 18: 205-216. PMID: 35273385, DOI: 10.1038/s41584-022-00761-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntirheumatic AgentsDouble-Blind MethodHumansQuality of LifeSeverity of Illness IndexSpondylitis, AnkylosingTreatment OutcomeConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoLManaging rheumatic diseases during COVID-19
Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clinical Rheumatology 2020, 39: 3245-3254. PMID: 32895747, PMCID: PMC7476772, DOI: 10.1007/s10067-020-05387-8.Peer-Reviewed Original ResearchConceptsAutoimmune rheumatic diseasesRheumatic diseasesImmunosuppressive agentsRheumatology practiceCOVID-19Multisystem autoimmune rheumatic diseaseLong-term complicationsCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionDisease 2019 pandemicMode of spreadImmunosuppressant managementImmunosuppressant medicationsViral illnessOrgan failureClinical featuresAutoimmune diseasesSerious infectionsTreatment optionsEffective vaccineImmune systemMedicationsDiseasePatients
2017
Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus?
Danve AS, Kulkarni S. Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus? American Journal Of Therapeutics 2017, 24: e347-e350. PMID: 26103543, DOI: 10.1097/mjt.0000000000000297.Peer-Reviewed Original ResearchMeSH KeywordsAntirheumatic AgentsArthritis, RheumatoidBlood GlucoseDiabetes MellitusHumansInflammationInsulin ResistanceTumor Necrosis Factor-alphaConceptsRheumatoid arthritisGlycemic controlTNF inhibitorsInsulin resistanceInsulin sensitivityTumor necrosis factor inhibitorsTumor necrosis factor alphaConcomitant rheumatoid arthritisInflammatory rheumatic diseasesNecrosis factor inhibitorsNecrosis factor alphaIncident diabetesDiabetes mellitusRheumatic diseasesFactor inhibitorsProinflammatory cytokinesFactor alphaPatientsMellitusArthritisInhibitorsDiabetesInflammationCytokinesDiseaseTreat to Target in Axial Spondyloarthritis: What Are the Issues?
Danve A, Deodhar A. Treat to Target in Axial Spondyloarthritis: What Are the Issues? Current Rheumatology Reports 2017, 19: 22. PMID: 28386759, DOI: 10.1007/s11926-017-0648-6.Peer-Reviewed Original ResearchMeSH KeywordsAntirheumatic AgentsBiological ProductsDrug MonitoringEarly DiagnosisHumansSeverity of Illness IndexSpondylarthritisTreatment OutcomeConceptsT2T strategyAxial spondyloarthritisT2TPsoriatic Arthritis TrialRandomized clinical studyChronic medical conditionsLimited therapeutic optionsRoutine clinical practiceT strategyLack of evidenceAggressive managementPsoriatic arthritisRadiographic outcomesRheumatic diseasesRheumatoid arthritisClinical evidenceTherapeutic optionsArthritis trialsClinical trialsClinical studiesMedical conditionsClinical practiceTarget strategyArthritisSpondyloarthritis